Abstract:RANKL/RANK/OPG system consists of three essential signaling molecules: i) the receptor activator of nuclear factor (NF)-kB-ligand (RANKL), ii) the receptor activator of NF-kB (RANK), and iii) the soluble decoy receptor osteoprotegerin (OPG). Although this system is critical for the regulation of osteoclast differentiation/activation and calcium release from the skeleton, different studies have elucidated its specific role in mammary gland physiology and hormone-driven epithelial proliferation during pregnancy. Of note, several data suggest that progesterone induces mammary RANKL expression in mice and humans. In turn, RANKL controls cell proliferation in breast epithelium under physiological conditions typically associated with higher serum progesterone levels, such as luteal phase of the menstrual cycle and pregnancy. Hence, RANKL/RANK system can be regarded as a major downstream mediator of progesterone-driven mammary epithelial cells proliferation, potentially contributing to breast cancer initiation and progression. Expression of RANKL, RANK, and OPG has been detected in breast cancer cell lines and in human primary breast cancers. To date, dysregulation of RANKL/RANK/OPG system at the skeletal level has been widely documented in the context of metastatic bone disease. In fact, RANKL inhibition through the RANKL-blocking human monoclonal antibody denosumab represents a well-established therapeutic option to prevent skeletal-related events in metastatic bone disease and adjuvant therapy-induced bone loss in breast cancer. On the other hand, the exact role of OPG in breast tumorigenesis is still unclear. This review focuses on molecular mechanisms linking RANKL/RANK/OPG system to mammary tumorigenesis, highlighting pre-clinical and clinical evidence for the potential efficacy of RANKL inhibition as a prevention strategy and adjuvant therapy in breast cancer settings.

The Roadmap of RANKL/RANK Pathway in Cancer

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies

RANK pathway in cancer: underlying resistance and therapeutic approaches

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Targeting RANK/RANKL in the treatment of solid tumours and myeloma

Advances of RANKL/RANK Pathway in Tumorigenesis and Metastasis of Breast Cancer

Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives

Regulation of cancer cell migration and bone metastasis by RANKL

RANK in cancer-associated fibroblasts: A valuable prognostic determinant for metastasis in early-stage breast cancer patients

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis

Discovery of the RANKL/RANK/OPG system

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

RANKL regulates differentially breast cancer stem cell properties through its RANK and LGR4 receptors

Immunomodulatory Effects of RANK/RANKL Blockade in Patients with Cancer

RANKL and RANK as novel therapeutic targets for arthritis

Structural and Functional Insights of RANKL-RANK Interaction and Signaling.

Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer